Reasons for Hyperhidrosis, Its Effects, and Novel Therapies

***ABSTRACT***

Excessive sweating is a symptom of a long-term medical condition called hyperhidrosis. Despite affecting 2-3% of the global population, it is not considered a public health concern. Because of social taboos, patient discomfort, and a general lack of awareness among the medical community, hyperhidrosis is commonly misdiagnosed and undertreated despite its seriousness. The illness has a significant impact on not only physical but also psychological and social well-being, causing disturbances in everyday routines, occupational performance, and interpersonal relationships. This report provides an integrated overview of findings from significant investigations, including the underlying pathophysiology, epidemiology, diagnostic approaches, and long-term consequences on quality of life.

**Keywords**- Hyperhidrosis, Excessive Sweating, Sympathetic nervous system, Eccrine sweat glands, Aluminum chloride, Iontophoresis, Microwave Thermolysis, ETS- Endoscopic thoracic Sympathectomy, sofpironim bromide, HDSS- Hyperhidrosis Disease Severity scale, Psychosocial impact.

***INTRODUCTION***

Hyperhidrosis is a chronic and sometimes misunderstood medical condition characterized by sweating that exceeds the physiological needs for thermoregulation. Unlike regular sweating, which is a normal response to heat or physical effort, hyperhidrosis is characterized by persistent and uncontrollable perspiration that is frequently triggered by stress, emotional stimulation, or no known reason at all. This disorder affects about 2.8% of the world's population, while the true frequency could be greater due to considerable inadequate reporting. Many people with hyperhidrosis may not seek medical assistance, caused by embarrassment stigma, or the belief that their symptoms are simply personal hygiene issues rather than a serious health disease. There are two primary (idiopathic) and secondary types of hyperhidrosis. Usually starting in childhood or adolescence, primary hyperhidrosis is localized and affects particular areas including the face, palms, soles, and underarms.



Fig .1 Model of Hyperhidrosis

 Even though a genetic tendency has been identified in numerous instances, it is typically symmetrical and happens without any underlying medical conditions. However, secondary hyperhidrosis is frequently widespread and linked to recognizable causes including infections, cancer, neurological illnesses, endocrine problems (such hyperthyroidism), or adverse drug reactions. Since treatment plans and diagnostic techniques differ significantly between these two categories, it is important to distinguish between them. While primary hyperhidrosis usually requires symptom-targeted therapy, subsequent episodes of excessive sweating can frequently be resolved by addressing the underlying illness. Recent literature highlights the importance of recognizing hyperhidrosis as an illness in and of itself, one that requires committed medical care and investigation. Despite not being a life-threatening disorder, hyperhidrosis can have a major influence on a person's quality of life (QoL). Patients commonly report social interaction issues, emotional distress, avoidance behaviors, and poor performance at work or school, among other personal and professional concerns. These difficulties are frequently made worse by others' ignorance, particularly that of medical experts who might not be sufficiently trained to recognize or treat the medical condition. The impact of hyperhidrosis on quality of life is comparable to that of chronic dermatological conditions such severe psoriasis or skin irritation, if not greater. Therefore, improving the lives of those impacted by this underdiagnosed yet highly impacting disorder requires raising awareness, encouraging early diagnosis, and providing a wider range of effective treatment options.

***CLASSIFICATION***

Hyperhidrosis can be classified as:

• Primary hyperhidrosis usually starts in childhood or adolescence and is caused by a hereditary disease. It typically affects focus areas, such as the face, axillae, palms, and soles.

 • Systemic disorders such as hyperthyroidism, infections, or drug side effects can produce secondary hyperhidrosis, which is typically widespread.

Primary hyperhidrosis is idiopathic, whereas secondary hyperhidrosis is caused by other illnesses or drugs. Early start, symmetrical focal involvement (palms, soles, axillae), and a significant genetic predisposition are common characteristics of primary hyperhidrosis. Secondary hyperhidrosis can be asymmetrical or widespread, happens during the day and at night, and usually manifests later in life. Endocrine abnormalities, infections, neurological diseases, and adverse drug reactions from medications such as opioids and SSRIs are among the causes. According to epidemiological data, primary hyperhidrosis affects 2.8% of the US population, with greater incidence among young adults and students. However, many cases go unreported due to embarrassment or the normalization of symptoms.



Fig .2 Hyperhidrosis in body

***PATHOPHYSIOLOGY***

The human body's complex network of brain connections that regulate sweating synchronizes emotional and thermoregulatory reactions. Sweating has a vital physiological role in regulating body temperature, but it can become dysregulated in disorders like hyperhidrosis. The hypothalamus, a major brain region in charge of preserving internal homeostasis, oversees controlling thermoregulatory sweating. Nuclei, like the anterior and preoptic regions of the hypothalamus, play a special role in starting the production of sweat in response to rises in body temperature. The eccrine sweat glands, which are widely spaced on the forehead, axillae, palms, and soles, are eventually stimulated by these signals after they have passed through the sympathetic nervous system.On the other hand, higher brain regions like the limbic system and cerebral cortex mediate emotional sweating, which frequently manifests during stressful, anxious, or social settings. These areas are linked to behavioral reactions and emotional processing. In reaction to emotionally charged stimuli, signals from the limbic system activate sympathetic pathways, which activate eccrine glands, particularly those in the hands and face. This explains why, even in the absence of increased body temperatures, people with primary hyperhidrosis frequently report that their symptoms worsen during stressful or anxiety-inducing events. Research indicates that anatomical abnormalities in the sweat glands themselves are not the cause of excessive sweating in patients with primary hyperhidrosis. Rather, the sympathetic cholinergic fibers that control the eccrine glands are thought to be functionally hyperactive. The quantity and shape of sweat glands in affected people are within normal ranges, according to histopathological studies. This suggests that neurogenesis, not glandularity, is the fundamental pathology. Sweating excessively is just the result of the eccrine glands reacting to increased neurological impulses. Understanding this mechanism is critical for the development of specific treatments. Instead, then changing the anatomy of the glands themselves, treatments including sympathectomy, botulinum toxin injections, and anticholinergic drugs try to block or modify these hyperactive brain connections. These treatments can help restore normal sweating patterns and improve patient outcomes by addressing the underlying cause, which is dysregulated brain transmission.

***EPIDEMIOLOGY***
Although it is accepted that the rate of hyperhidrosis is between 2% and 3% worldwide, several researchers think that ongoing failing to report may have caused the true figures to be significantly greater. A considerable proportion of cases go untreated or are misdiagnosed as a result of people's reluctance to seek medical attention due to social stigma, embarrassment, and a general lack of information. A significant percentage of people with hyperhidrosis suffer awkward and ongoing symptoms that can significantly lower their quality of life. Adolescence or early adulthood, a time frequently linked to increased psychological sensitivity and social development, is when symptoms usually first appear. Because of this, the disease's impact can be very severe during these early years. Epidemiological statistics also show that hyperhidrosis presents differently depending on age group. For instance, elderly people are more likely to have axillary hyperhidrosis, while children and young adults are more likely to have palmar hyperhidrosis. These variances make it difficult to adequately estimate the condition's true frequency and impact across populations.The clinical diagnosis of hyperhidrosis is based on detailed medical history and a specific pattern of symptoms. There are several objective technologies available to help in disease diagnosis and quantification. A patient-reported outcome measure, the Hyperhidrosis Disease Severity Scale (HDSS) assesses how much sweating affects every day functioning and overall health. By measuring sweat absorbed on filter paper, gravimetric testing yields measurable data and an objective measurement. The starch-iodine test, sometimes referred to as Minor's test, helps in treatment planning by visually identifying hyperactive sweat zones by forming a purple-black coloration when sweat, iodine, and starch come into contact. Differentiating primary from secondary hyperhidrosis is a crucial part of the diagnostic procedure. Primary hyperhidrosis appears as uniform, localized sweating that starts early and runs in the family. Secondary hyperhidrosis, on the other hand, often develops later in life, can be uneven or generalized, and is frequently linked to underlying systemic illnesses such infections, endocrine problems, or severe drug reactions. To rule out secondary causes and direct appropriate care, further research should be resulted in by the existence of night sweats, sudden start of symptoms, or similar system signaling.

***IMPACT ON PSYCHOSOCIAL ISSUES AND QUALITY OF LIFE***

Hyperhidrosis has a significant impact on people's quality of life, hurting them physically, emotionally, socially, and economically. Seventeen key elements that highlight the extent to which the condition interferes with day-to-day functioning were found by Kamudoni et al. (2017). Sweat interference makes it difficult for people with hyperhidrosis to perform daily tasks like writing, handling things, or using electronics. In the workplace, it may limit career progression and limit productivity, especially in positions involving hard labor or a lot of social engagement.



Fig .3 Symptoms of Hyperhidrosis

Emotionally, people often suffer from anxiety, depression, and embarrassment, social detachment and low self-esteem get worse by the anxiety of being judged by others and of sweating visibly. To avoid embarrassment, many patients avoid relationships, public appearances, handshakes, and recreational activities, which feed the cycle of loneliness and suffering. People with hyperhidrosis make lifestyle decisions about their nutrition, personal cleanliness, and even their clothes to control their symptoms and stay away from triggers. Despite the heavy burden, many people express frustration with the lack of knowledge and assistance from medical providers. Psychological stress may be increased by misdiagnosis and therapy due to misunderstandings of the condition. Overall, hyperhidrosis is more than just a physical problem; it is a traumatic condition that affects all parts of life.

 ***CURRENT TREATMENTS***

***Topical Treatments-*** The initial course of treatment for mild to severe hyperhidrosis is usually topical treatments.

Commonly advised antiperspirants that block sweat gland ducts are made of ***aluminum chloride***. Despite their effectiveness, they might irritate skin, particularly in delicate spots.

Anticholinergic wipes containing glycopyrronium tosylate and glycocopyrrolate reduce sweating with little systemic absorption. The FDA has approved glycopyrronium tosylate especially for the treatment of axillary hyperhidrosis.

As it becomes more accessible, the more recent topical anticholinergic sofpironium bromide may provide a handy, low-risk substitute. It has demonstrated promising outcomes in clinical trials.

***Oral Medications***

When sweating is more severe, systemic anticholinergic drugs like oral glycopyrrolate and oxybutynin are used. They function by decreasing cholinergic activity, although they are frequently hindered by adverse effects like diarrhea, dry mouth, blurred vision, and urine retention.

***Medical Procedures***

1. **Injections of botulinum toxin**, which block nerve signals to sweat glands, are very successful for treating focal hyperhidrosis, particularly in the hands and underarms. However, they can be expensive and require recurrent treatments.
2. **Iontophoresis,** which temporarily reduces sweating by passing a mild electrical current through water, is very helpful for palmar and plantar hyperhidrosis.
3. A non-invasive, long-term remedy is provided by **microwave thermolysis** (e.g., miraDry), which use thermal energy to permanently destroy sweat glands in the axillae.

***Surgical Options***

Sweat gland activation is stopped by cutting sympathetic nerves during an **endoscopic thoracic sympathectomy** (ETS). Due to severe side effects, such as compensatory sweating, gustatory sweating, and the possibility of Horner's syndrome, this once-common remedy is now used less frequently. For severe, treatment-resistant situations, it is typically regarded as a last resort.

  

 Fig .4 Injections of botulinum toxin Fig.5 Iontophoresis

  

 Fig.6 Microwave Thermolysis Fig .7 Endoscopic thoracic sympathectomy

 ***FUTURE PERSPECTIVES***

* Topical medications like sofpironium bromide and glycopyrronium bromide are becoming more popular due to their limited systemic absorption and localized effects.
* Wearable technology and biosensor advancements are making it possible to measure sweat in real time, opening the door to individualized treatment plans.
* In ongoing clinical trials, novel formulations such as transdermal oxybutynin and liposomal botulinum toxin lotions are showing future potential.
* To improve the efficacy of treatment, combination strategies that include topical and systemic medicines are being investigated.
* To reduce side effects and increase patient compliance, targeted drug delivery methods are being developed.
* The goal of ongoing wearable biosensor research is to improve treatment by using dynamic sweat rate data.
* Furthermore, interest in potential future treatments is being sparked by experimental techniques including gene-based treatment and non-invasive neuromodulation.



Fig 8. WEARABLE BIOSENSOR DEVICES

***CONCLUSION***

Hyperhidrosis is a life-altering condition that necessitates quick medical attention. Improving patient care requires a deep comprehension of its causes, impacts, and developing therapeutic choices. Even with advancements in medication and device-based treatments, there are still a lot of unanswered questions, especially when it comes to finding individualized and effective treatments. This common yet rarely overlooked condition has substantial social, emotional, and physical consequences. Increasing public and clinical awareness, encouraging early diagnosis, and funding research for breakthrough therapeutics are critical steps toward meeting the needs of people affected by this "silent" condition.

***REFERENCES***

|  |  |
| --- | --- |
| 1.
 | Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Nowicki RJ. Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities. Postepy Dermatol Alergol [Internet]. 2022;39(2):251–7. Available from: <http://dx.doi.org/10.5114/ada.2022.115887> |

1. Rystedt, A., Brismar, K., Aquilonius, S., Naver, H., & Swartling, C. (2016, July 21). *Hyperhidrosis - an unknown widespread “silent” disorder*. <https://www.jneurology.com/articles/hyperhidrosis--an-unknown-widespread-silent-disorder.htmls>
2. Kamudoni, P., Mueller, B., Halford, J., Schouveller, A., Stacey, B., & Salek. (2017). The impact of hyperhidrosis on patients’ daily life and quality of life: a qualitative investigation. *Health and Quality of Life Outcomes*, *15*(1). https://doi.org/10.1186/s12955-017-0693-x
3. Hasimoto, E. N., Cataneo, D. C., Reis, T. A. D., & Cataneo, A. J. M. (2018). Hyperhidrosis: prevalence and impact on quality of life. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia*, *44*(4), 292–298. <https://doi.org/10.1590/S1806-37562017000000379>
4. Shayesteh A, Brulin C, Nylander E. The Meaning of Living for Men Suffering From Primary Hyperhidrosis. American Journal of Men’s Health. 2019;13(6). doi:10.1177/1557988319892725
5. Lenefsky, M., & Rice, Z. P. (2018). Hyperhidrosis and its impact on those living with it. *The American journal of managed care*, *24*(23 Suppl), S491–S495.
6. Gelbard, C. M., Epstein, H., & Hebert, A. (2008). Primary Pediatric Hyperhidrosis: A review of current treatment options. *Pediatric Dermatology*, *25*(6), 591–598. <https://doi.org/10.1111/j.1525-1470.2008.00782.x>
7. Torrisi, B., Zarnitsyn, V., Prausnitz, Anstey, A., Gateley, C., Birchall, J., & Coulman, S. (2012). Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin. *Journal of Controlled Release*, *165*(2), 146–152. https://doi.org/10.1016/j.jconrel.2012.11.010
8. Rzany, B., Müller, C., & Hund, M. (2012). Fokale hyperhidrose. *Der Hautarzt*, *63*(6), 456–461. https://doi.org/10.1007/s00105-012-2331-1
9. *Hyperhidrosis: management options*. (2018, June 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/30215934/
10. Kaufmann, H., Saadia, D., Polin, C., Hague, S., Singleton, A., & Singleton, A. (2003). Primary hyperhidrosis. *Clinical Autonomic Research*, *13*(2), 96–98. https://doi.org/10.1007/s10286-003-0082-x
11. Park, E. J., Han, K. R., Choi, H., Kim, D. W., & Kim, C. (2010). An epidemiological study of hyperhidrosis patients visiting the Ajou University Hospital Hyperhidrosis Center in Korea. *Journal of Korean Medical Science*, *25*(5), 772. <https://doi.org/10.3346/jkms.2010.25.5.772>
12. Rashmeen, S., Sohail, I., Mohsin, M., Anwar, D., Farhat, S., Shahnoor, S., Maryyum, A., & Khan, A. M. (2025). Sofpironium bromide: a novel solution in the battle against primary axillary hyperhidrosis. *Annals of Medicine and Surgery*, *87*(5), 2526–2528. https://doi.org/10.1097/ms9.0000000000003093
13. Ji, W., Zhu, J., Wu, W., Wang, N., Wang, J., Wu, J., Wu, Q., Wang, X., Yu, C., Wei, G., Li, L., & Huo, F. (2021). Wearable sweat biosensors Refresh Personalized Health/Medical Diagnostics. *Research*, *2021*. https://doi.org/10.34133/2021/9757126
14. Frasier, K. M., Hash, M. G., & Pugliese, A. (2025). Wearable sensor Technology for hyperhidrosis management in individuals with prosthetic limbs: A Narrative review. *Cureus*. https://doi.org/10.7759/cureus.79109
15. Gregoriou, S., Sidiropoulou, P., Kontochristopoulos, G., & Rigopoulos, D. (2019). <p>Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions</p> *Clinical Cosmetic and Investigational Dermatology*, *Volume 12*, 733–744. https://doi.org/10.2147/ccid.s210973
16. Zhao, L., Chen, J., Bai, B., Song, G., Zhang, J., Yu, H., Huang, S., Wang, Z., & Lu, G. (2024). Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing. *Frontiers in Pharmacology*, *14*. https://doi.org/10.3389/fphar.2023.1333986
17. Min, J., Tu, J., Xu, C., Lukas, H., Shin, S., Yang, Y., Solomon, S. A., Mukasa, D., & Gao, W. (2023). Skin-Interfaced wearable sweat sensors for precision medicine. *Chemical Reviews*, *123*(8), 5049–5138. https://doi.org/10.1021/acs.chemrev.2c00823
18. Davidson, B., Bhattacharya, A., Sarica, C., Darmani, G., Raies, N., Chen, R., & Lozano, A. M. (2024). Neuromodulation techniques – From non-invasive brain stimulation to deep brain stimulation. *Neurotherapeutics*, *21*(3), e00330. https://doi.org/10.1016/j.neurot.2024.e00330
19. Parashar, K., Adlam, T., & Potts, G. (2023). The Impact of Hyperhidrosis on Quality of life: A review of literature. *American Journal of Clinical Dermatology*, *24*(2), 187–198. https://doi.org/10.1007/s40257-022-00743-7